General anesthesia or conscious sedation in paroxysmal atrial fibrillation catheter ablation

Ondrej Moravec, Tomas Skala, Olga Klementova, Jitka Skalova, Martin Hutrya, Jan Precek, Marian Fedorco, Vlastimil Cerníček, Zbyněk Tudos, Jana Zapletalová, Miloslav Taborsky

Background. Catheter ablation of paroxysmal atrial fibrillation (AF) can be performed under general anesthesia or conscious sedation. The influence of type of anesthesiology care on procedural characteristics and ablation outcome in patients in whom intracardiac echocardiography (ICE) and elimination of adenosine-mediated dormant conduction (DC) is used is not entirely known.

Methods. 150 patients with paroxysmal AF were randomized to point-by-point radiofrequency catheter isolation of pulmonary veins (PVI) under general anesthesia (n=77) or conscious sedation (n=73). Adenosine-mediated dormant conduction was eliminated in all patients. Antiarrhythmic medication was discontinued after PVI. During twelve months of follow-up, all patients underwent four times 7-day ECG monitorings.

Results. There was no difference between groups in AF recurrence (28.6% vs. 31.5%, P=0.695). Patients in conscious sedation had longer procedure times (160 ± 32.1 vs. 132 ± 31.5 min, P<0.001), longer RF energy application times (40 ± 15 vs. 29 ± 11 min, P<0.001) and longer fluoroscopy times (6.2 min ± 5.3 vs. 4.3 min ± 2.2, P<0.001) with similar complication rates.

Conclusion. Conscious sedation is not inferior to general anesthesia in regard to arrhythmia recurrence or complication rates of catheter ablation of paroxysmal atrial fibrillation. However, it is associated with longer procedure times, longer time of radiofrequency energy application and longer fluoroscopy times.

Key words: general anesthesia, conscious sedation, atrial fibrillation, catheter ablation, adenosine, dormant conduction, arrhythmia recurrence, intracardiac echocardiography

Received: November 16, 2019; Revised: March 10, 2020; Accepted: March 10, 2020; Available online: April 6, 2020
https://doi.org/10.5507/bp.2020.012
© 2021 The Authors; https://creativecommons.org/licenses/by/4.0/

BACKGROUND

Atrial fibrillation (AF) is the most common sustained arrhythmia. It remains to have a significant impact on cardiovascular morbidity1. Catheter ablation (RFA) is significantly more effective in terms of arrhythmia recurrence rate than antiarrhythmic medication2. Dominant sources of triggers starting AF are in pulmonary veins (PV). PV isolation (PVI) is thus the cornerstone of the non-pharmacological treatment of paroxysmal AF (ref.3). RFA is a complex procedure that can last for several hours. For the duration of the procedure, the patient needs to remain motionless on the operation table. This is by itself far from comfortable. Moreover, the radio-frequency (RF) energy is very often perceived as very painful. With regards to painfulness of this procedure, some type of anesthesiology care is undoubtedly necessary. Generally speaking, two options are available: conscious sedation and general anesthesia.

Conscious sedation (CS) refers to administration of pain-relieving drugs resulting in a quantitative influence on consciousness, with spontaneous ventilation preserved.

General anesthesia (GA) refers to a treatment procedure resulting in an elimination of perception of all stimuli, including pain. The ability to breathe spontaneously may be impaired based on the level of anesthesia.

There are several studies comparing these two approaches. Data on the impact of the type of anesthesiology care in patients in whom intracardiac echocardiography (ICE) and elimination of adenosine-mediated dormant conduction (DC) is used are very scarce.

METHODS

Study design

This study is a non-commercial, investigator-initiated, single-center, prospective, randomized, open-label, interventional, parallel-design trial.

We aim to evaluate the impact of the type of anesthesiology care on RFA of paroxysmal AF.
Clinical hypothesis
When using ICE, computed tomography (CT) model of left atrium (LA) merged with LA electro-anatomical map and elimination of DC after adenosine challenge, CS is not inferior to GA regarding the arrhythmia recurrence rate after RFA of paroxysmal AF.

Inclusion criteria
Paroxysmal AF; ≥3 episodes of AF in the last 6 months documented on ECG or on a Holter ECG monitoring; Sinus rhythm (SR) at the beginning of RFA; Age > 18 years; a signed informed consent for the study (ICF).

Exclusion criteria
Persistent or long-standing persistent AF; Structural heart disease; Moderate-to-severe or severe valve disease or history of a valve disease surgery; Left ventricular ejection fraction (LVEF) <35%; Presence of intra-cardiac thrombi; Pregnancy; Breast feeding; Uncorrected congenital heart disease; Obstructive cardiomyopathy; Active myocarditis; Constrictive pericarditis; Untreated hypothyroidism or hyperthyroidism; Chronic kidney disease with a glomerular filtration rate <30 mL/min; Chronic dialysis treatment; Presence on the urgent waiting list for a heart transplant; Recipient of any major organ transplant; Malignancy; Known to be human immunodeficiency virus positive; History of alcohol or illicit drug abuse disorder.

The primary end-point
Arrhythmia recurrence rate twelve months after catheter ablation.

The secondary end-points
RFA procedure duration; Fluoroscopy time; Total RFA burn time.

Patient group
A total of 150 patients indicated for RFA of paroxysmal AF were included in the study. Patients were classified as having paroxysmal AF according to current guidelines.

The written ICF was obtained from all subjects.

Procedures before catheter ablation
Transesophageal and transthoracic echocardiography within 24 hours before RFA. Cardiac CT focused on PV anatomy within 7 days before RFA.

Echocardiography
A standardized trans-thoracic and trans-esophageal echocardiography were done in all patients 1-24 hours before RFA. Intracardiac thrombi were excluded.

The measured parameters were LA diameter in parasternal long axis view, LA volume, LVEF, left atrial appendage (LAA) outflow speed (cm/s).

Computed tomography
64-slice LightSpeed VCT scanner (General Electrics, Milwaukee, USA) was used in all participants.

The range of the examination was from the bifurcation of the trachea to the heart apex.

CT parameters: tube voltage of 120 kV, pitch 0.984:1, collimation 64×0.625 mm and gantry rotation 0.4 s, ECG gating was not used.

The participants in both groups received intravenously 70 mL of the iodinated contrast agent Iopromide (Ultravist® 370, Bayer Healthcare, Berlin, Germany) with a flow rate of 4 mL/s, followed by 30 mL of saline flush. The delay of data acquisition was triggered using the "bolus tracking" technique; the region of interest was located in the LA.

All examinations were performed with anatomically adapted tube current modulation based on attenuation profiles in the antero-posterior and lateral directions.

The CT images were reconstructed with a slice thickness of 0.625 mm using the standard filtered back-projection method with kernel Standard.

Randomization
Patients were randomized in a 1:1 ratio to receive either GA (n = 77) or CS (n = 73).

Anticoagulation therapy management before catheter ablation
Oral anticoagulation was uninterrupted during the ablation procedure in case of Warfarin.

In case of direct anticoagulants one dose was skipped before ablation. This dose was administered immediately after the end of ablation.

Anesthetic care
Blood pressure was measured invasively using right radial arterial line in all patients.

General anesthesia
At the beginning of the procedure, before femoral veins cannulation, we intravenously administered sufentanil (Sufentanil Torrex; 0.5 µg/kg), propofol (Diprivan; 1-2 mg/kg) and rocuronium (Esmeron; 0.6 mg/kg) with a subsequent orotracheal intubation and mechanical ventilation. The GA was then managed using an inhalation anesthetics sevoflurane (Svorane Baxter; 100%) to achieve minimal alveolar concentration (MAC) 0.7. Sufentanil (5-10 µg) was administered as a single dose intermittently when needed. Pressure-controlled mechanical ventilation was used with a volume of 7-8 mL/kg and ventilation rate of 10-12 breaths/min. When the mean arterial pressure dropped below 65 mmHg, noradrenaline (norepinephrine 1,000 µg/mL; 0.5-12 µg/min to achieve mean arterial pressure above 65 mmHg) was used. After RFA, patients were extubated and subsequently monitored on an intermediate in-patient department until the next morning.

Conscious sedation
At the beginning of the procedure, before femoral veins cannulation, we administered fentanyl (Fentanyl Torrex 50 µg/mL; 100 µg single dose) intravenously and started a continuous infusion of midazolam hydroclo-
ride (Dormicum; 0.03-0.2 mg/kg/h). The speed of the continuous infusion was titrated to achieve the level of sedation (Richmond Agitation-Sedation Scale) RASS -2 to -3. Femoral veins were cannulated with local anesthesia using Supracain 4% (1 mL of Supracain contains 40 mg of articaine hydrochloride and 0.006 mg of epinephrine hydrochloride), 6 mL in each groin.

After RFA, patients were monitored on an intermediate in-patient department until the next morning.

Catheter ablation
Two steerable transseptal sheaths (Agilis™ NxT Steerable Introducer, St. Jude Medical) were introduced via right femoral vein.

Two sheaths were introduced via left femoral vein for intra-cardiac echocardiography probe (AcuNav ultrasound catheter, Siemens Healthineers, USA) and decapolar diagnostic coronary sinus catheter (Inquiry™, St. Jude Medical).

Access to LA was acquired via double transseptal puncture. We have used Carto3™ ( Biosense Webster) in all patients to get a 3D electro-anatomical map. We have used a fast-anatomical map (FAM) consistently in all patients. CartoMerge™ technology was used to merge electro-anatomical map with CT model. Navistar™ ablation catheter (Biosense Webster) was used for a point-by-point wide-antral RFA (Pic. 1) in all patients to achieve isolation of ipsilateral PVs.

Ablation energy was set to 25-30 W with cool flow of 20 mL/min. To validate PV isolation (entry block), Lasso ™ catheter (Biosense Webster) was used. A direct current cardioversion was performed in case of ongoing AF prior to final check for PVI. After PVI, we did not use inducibility testing or provocation of extra-pulmonary triggers. We waited for 20 min after PVI and then we intravenously applied adenosine to test for a dormant conduction. At least 18 mg of adenosine was used for the test.

A second- or third-degree atrioventricular block was needed for the dose of adenosine to have been considered sufficient.

In PVs with conduction recovery after adenosine testing, additional ablation was performed until DC was eliminated. The procedure was ended, once all PVs with conduction recovery were re-isolated.

Subsequently, the catheters were retracted from LA and based on the administered dose of heparin, a protamine-sulfate (Protamin ME; 5000 I.U./mL) was administered to negate the heparin effect. A peroral anticoagulation was started immediately or it went on in case of a non-interrupted anticoagulation.

Wide encircling lesions around ostia of ipsilateral pulmonary veins (CARTO3 electroanatomical model of left atrium, superposition with computed tomography model; postero-anterior view). Red dots = ablated areas.

RFA procedure duration definition
Time from when the patient laid on the operation table until he or she was transferred into a hospital bed fully conscious.

Follow-up post-ablation
All antiarrhythmic medication was stopped immediately after RFA. All patients were followed in the outpatient department of our institution during the whole follow-up (FU).

A blanking period was set as 0-3 months after RFA. Arrhythmia recurrence was managed using antiarrhythmic medication and cardioversion if necessary. During the blanking period, AF recurrences were not considered an RFA failure and a cardioversion was allowed. Antiarrhythmic drugs were also allowed during the blanking period.

The first clinical visit was performed before the end of the third month after RFA and at this visit all potential antiarrhythmic medication was stopped if it was not stopped before. Antiarrhythmic drugs were not allowed after the end of third month or their use was considered as ablation failure / arrhythmia recurrence. Amiodarone was not allowed after RFA or its use was considered as ablation failure / arrhythmia recurrence.

Every 3 months after RFA (3, 6, 9 and 12 months after RFA), a 7-days ambulatory ECG monitoring was done in all patients.

Any documented arrhythmia lasting more than 30 seconds was considered as an arrhythmia recurrence.

Statistical evaluation
Statistical analysis was done the 12th month after ablation. The statistical software IBM SPSS Statistics ver. 22 was used to data analysis.

For nominal parameters, the subgroups of patients were compared using Chi-square test or Fisher’s exact test. Continuous parameters were compared using t Mann-Whitney U-test. Data normality was tested using Shapiro-
Wilk test. The results are presented as means±SD and the level of significance was 0.05.

RESULTS

The difference between groups
A total of 150 patients were enlisted in the study, 105 men and 45 women. The baseline clinical and echocardiographic characteristic of the group are depicted in Table 1. There was no significant difference between CS and GA in any baseline clinical or echocardiographic parameter except for a more frequent statin therapy in the CS group.

Additional catheter ablation after pulmonary veins isolation
In this patient group, we did not perform any additional catheter ablation after PVI except CTI in some cases. There was no significant difference between CS and GA in number of CTI ablations (Table 2).

Procedural characteristics
RFA in the CS group lasted longer (160 min ± 32.1 vs. 132 min ± 31.5, P<0.001). A total burn time (total length of RF energy application) was longer in the CS group (40 ± 15 vs. 29 ± 11 min, P<0.001). Also, total fluoroscopy time was longer in the CS group (6.2 min ± 5.3 vs. 4.3 min ± 2.2, P<0.001). These parameters are summed in Table 3 and depicted in Fig. 2, 3, 4.

Adenosine-mediated dormant conduction
After PVI and a subsequent adenosine administration, DC was present in 23 patients (40.4%) in the CS group and in 24 patients (34.3%) in the GA group. The difference was not significant (Table 4).

Table 1. Baseline clinical and echocardiographic characteristics of the patient group.

<table>
<thead>
<tr>
<th></th>
<th>Conscious sedation</th>
<th>General anesthesia</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex</td>
<td>54 (70%)</td>
<td>51 (69.9%)</td>
<td>0.972</td>
</tr>
<tr>
<td>Age</td>
<td>56.2 ± 10.9</td>
<td>56.9 ± 11</td>
<td>0.574</td>
</tr>
<tr>
<td>Weight</td>
<td>91.8 ± 17.3</td>
<td>87.6 ± 17.4</td>
<td>0.137</td>
</tr>
<tr>
<td>Body mass index</td>
<td>28.6 ± 4.9</td>
<td>28.3 ± 4.4</td>
<td>0.542</td>
</tr>
<tr>
<td>LA diameter (mm)</td>
<td>41.7 ± 6.4</td>
<td>42.1 ± 6.6</td>
<td>0.767</td>
</tr>
<tr>
<td>LAA outflow velocity (cm/s)</td>
<td>79.3 ± 28.2</td>
<td>70.3 ± 28.0</td>
<td>0.061</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>56.4 ± 6.0</td>
<td>56.6 ± 4.2</td>
<td>0.389</td>
</tr>
<tr>
<td>Arterial hypertension</td>
<td>44 (60.3%)</td>
<td>48 (62.3%)</td>
<td>0.867</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>7 (9.6%)</td>
<td>9 (11.7%)</td>
<td>0.794</td>
</tr>
<tr>
<td>Heart failure</td>
<td>3 (4.1%)</td>
<td>5 (6.5%)</td>
<td>0.720</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>2 (2.7%)</td>
<td>4 (5.2%)</td>
<td>0.682</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>1 (1.4%)</td>
<td>3 (3.9%)</td>
<td>0.620</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>28 (38.4%)</td>
<td>23 (29.9%)</td>
<td>0.304</td>
</tr>
<tr>
<td>Stroke</td>
<td>4 (5.5%)</td>
<td>6 (7.9%)</td>
<td>0.746</td>
</tr>
<tr>
<td>Propafenone</td>
<td>25 (34.2%)</td>
<td>28 (36.4%)</td>
<td>0.865</td>
</tr>
<tr>
<td>Sotalol</td>
<td>7 (9.6%)</td>
<td>5 (6.5%)</td>
<td>0.556</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>17 (23.3%)</td>
<td>16 (20.8%)</td>
<td>0.844</td>
</tr>
<tr>
<td>Dronedarone</td>
<td>1 (1.4%)</td>
<td>0 (0%)</td>
<td>0.487</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>48 (65.8%)</td>
<td>57 (74.0%)</td>
<td>0.290</td>
</tr>
<tr>
<td>Statin</td>
<td>27 (37.0%)</td>
<td>16 (20.8%)</td>
<td>0.032</td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>16 (21.9%)</td>
<td>15 (19.5%)</td>
<td>0.84</td>
</tr>
<tr>
<td>ACE inhibitors</td>
<td>29 (39.7%)</td>
<td>27 (35.1%)</td>
<td>0.614</td>
</tr>
<tr>
<td>Angiotensin II receptor blockers</td>
<td>9 (12.3%)</td>
<td>17 (22.1%)</td>
<td>0.134</td>
</tr>
</tbody>
</table>

Table 2. Cavotricuspid isthmus ablation.

<table>
<thead>
<tr>
<th></th>
<th>Conscious sedation</th>
<th>General anesthesia</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cavotricuspid isthmus ablation</td>
<td>28 (38.4%)</td>
<td>30 (39.0%)</td>
<td>0.939</td>
</tr>
</tbody>
</table>

Table 3. Catheter ablation characteristics.

<table>
<thead>
<tr>
<th></th>
<th>Conscious sedation</th>
<th>General anesthesia</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procedure time (min)</td>
<td>159.6 ± 31.5</td>
<td>137.2 ± 32.1</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Fluoroscopy time (min)</td>
<td>6.2 ± 5.3</td>
<td>4.3 ± 2.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total burn time (min)</td>
<td>43.2 ± 15.1</td>
<td>31.2 ± 11.1</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>
Complications of catheter ablation

Two patients presented with a femoral artery pseudoaneurysm (1 in CS group, 1 in GA group). One case was resolved using an ultrasound-guided manual compression; the other patient had to undergo surgery. In the CS group, we documented one case of a transient ischemic attack manifested as diplopia. The neurological symptoms receded completely in less than 60 min. A subsequent CT of the brain revealed no signs of ischemia. In the whole group, there were no cases of cardiac tamponade, atrioesophageal fistula, stroke or any other severe complication.

Arrhythmia recurrence rate after ablation

At the end of the ablation procedure, all PVs were isolated in all patients. 12 months after RFA, an arrhythmia recurrence was documented in 23 patients (31.5%) in the CS group and in 22 patients (28.6%) in the GA group. The difference was not significant (Table 5).

DISCUSSION

Due to different pain thresholds, sedation is not entirely effective in some patients. A painful RFA cannot only be subjectively unpleasant but it can also lead to a movement of the patient with an electro-anatomical map shift. This may lead to an unsatisfactory localization of anatomical details in the cardiac chamber of interest or to a need for a new map. Either of these cases can lead to prolongation of the procedure. Considerable respiratory excursions cause by painful RF applications also worsen contact of the catheter with myocardial tissue. Using catheters with contact-force, Chikata et al. demonstrated that RFA in GA improves the contact force and thus increases the rate of PVI made by just one encircling lesion (first pass PVI) (50.5% vs. 34.8%, \( P = 0.04 \)) (ref.4).

Generally speaking, GA is perceived as a procedure extending the duration of RFA but the opposite was true in our study. We demonstrated that a complete elimination of painful perceptions during GA makes RFA faster. The absence of stopping of RF energy applications, significant patient movement and excessive respiratory excursions leads to a shorter total RF energy application time (total burn time) and also to a shorter fluoroscopic time.

Table 4. The presence of adenosine-mediated dormant conduction.

<table>
<thead>
<tr>
<th></th>
<th>Conscious sedation</th>
<th>General anesthesia</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dormant conduction</td>
<td>23 (40.4%)</td>
<td>24 (34.3%)</td>
<td>0.58</td>
</tr>
</tbody>
</table>

Table 5. Arrhythmia recurrence rate after catheter ablation.

<table>
<thead>
<tr>
<th></th>
<th>Conscious sedation</th>
<th>General anesthesia</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arrhythmia recurrence rate</td>
<td>23 (31.5%)</td>
<td>22 (28.6%)</td>
<td>0.695</td>
</tr>
</tbody>
</table>
It is inadvisable to underestimate even the subjective unpleasant perception itself. Fewer patients ablated in CS are willing to undergo a repeated procedure compared to patients ablated in GA (ref. 1).

It could be tempting to blame a poorly led CS for the painful perceptions. But the pain threshold and tolerance differ from patient to patient. In a small number of patients, due to significant painful sensations, it is very difficult to finish RFA despite potent doses of analgesics. On the other hand, it is not difficult to administer an excessive dose of analgesics in such a situation, leading to a cessation of breathing. This obviously results in a rapid response in regards of the patients' management and often also to a significant movement of his or her body and a need to make a new electro-anatomical map.

A very calm course of RFA under GA in our study was associated with a decrease in the procedure length. This was also documented in the study by Di Biase et al. with a shorter procedure length in GA patients (2.4 ± 1.4 vs 3.6 ± 1.1 h, P<0.01) (ref. 6). Other trials had different results. Wasserlauf et al. presented outcomes in Cryoballoon ablation patients. In their study, a moderate sedation reduced laboratory time compared to GA (280.4 ± 54.1 min vs 245.5 ± 54.7 min, P<0.001) (ref. 7). In a study with remote magnetic ablation, Bun et al. concluded that GA is not superior to local anesthesia (237 ± 50 min vs. 240 ± 61 min, P=0.84) (ref. 8). In a small randomized trial with RF energy ablation, overall procedural times were comparable in GA and analgesedation groups (111.2 ± 16.3 min vs 104.8 ± 25 min, P = NS) (ref. 9).

Painful sensations during RFA can lead to a need for a decrease in RF energy output and a potentially inefficient ablation. Di Biase et al. demonstrated a higher long-term RFA efficacy in GA patients (88% vs 69%, P<0.001) and also a lower PV reconnection rate during a redo procedure (19% vs 42%, P=0.003) (ref. 10). On the contrary, studies with remote magnetic ablation3 and Cryobaloon1 documented similar long-term arrhythmia recurrence rate in CS and GA patients.

We can potentially demonstrate an insufficient RFA in CS patients using an adenosine test. We have already demonstrated, that by elimination of DC by additional ablation it is possible to equalize long-term arrhythmia recurrence rate in patients with DC and without DC (ref. 19). In our study, we documented no significant difference in the presence of adenosine-mediated DC between the SC and GA groups. We thus have no evidence of an insufficient ablation in any of those groups. We can only speculate that the reason could be a constant employment of ICE with a real-time monitoring of the movement and localization of the ablation catheter. However, the presence of DC can be influenced by the type of anesthetic care. Narui et al. documented an adenosine-mediated DC more frequently in patients in a deeper sedation in comparison with a milder sedation (19.2% vs 13.0%, P=0.01). In our study, we did not observe a significant difference in the presence of DC between the groups. Without data from a redo procedure, we can only speculate if this is caused by a comparably effective CS and GA in similarly performed PVI or by differently effective CS and GA, counterbalanced with a differently performed RFA. Nevertheless, we have shown that we can achieve comparable RFA outcomes in CS and GA patients if we use ICE and eliminate potential DC.

We can also only speculate that the minimal complications rate in our study, and none directly linked to GA, is due to the routine employment of ICE. Potential thrombi could be sucked out before manifestation of a cardioembolic event even during GA. One can lower the power setting of RF energy delivery when the catheter is in a close proximity to esophagus on ICE image and does not need to rely on a pain sensation told by the patient in CS.

We did not confirm the often-mentioned concern about a higher complication rate in GA patients.

**Study limitations**

This study was not blinded but blinding was not feasible due to the nature of the study.

The study power was not analysed before the trial. Thus the number needed to confirm statistical significance may not have been met. Nevertheless, the number of patients included in this trial was comparable with similar trials. This trial was single-centre only. In our institution, for AF ablation, GA is mainly used. This might be a source of potential error and one probable explanation for the differences between groups. Significantly more men than women were included, however without a significant difference in the rate of men between CS and GA. In this patient group, we did not perform any additional RFA after PVI, except a CTI ablation in a significant percentage of the patient group. Even a slight possibility of typical atrial flutter on any previous ECGs led us to CTI ablation. The ratio of this ablation was higher in comparison with previous studies7 since our threshold for a CTI ablation is significantly lower because of the simplicity, safety and efficacy of this ablation procedure when steerable sheaths and ICE are available. Nevertheless, there was no significant difference in CTI ablations rate between CS and GA. Another potential study limitation is the absence of contact-force catheters. These were not routinely available at our institution at the beginning of the study and we did not use them in these patients from there on in order not to distort the results of the study.

**CONCLUSION**

Conscious sedation is not inferior to general anesthesia regarding arrhythmia recurrence or complication rate of catheter ablation of paroxysmal atrial fibrillation. However, it is associated with longer procedure times, longer radiofrequency energy application duration and longer fluoroscopy times.

**ABBREVIATIONS**

AF, Atrial fibrillation; RFA, Catheter ablation; RF, Radio-frequency; PV, Pulmonary veins; PVI, Pulmonary veins isolation; CS, Conscious sedation; CA, General
anesthesia; ICE, Intracardiac echocardiography; DC, Dormant conduction; LVEF, Left ventricular ejection fraction; SR, Sinus rhythm; INR, international normalized ratio; FU, Follow-up; LA, Left atrial; CT, Computed tomography; LAA, Left atrial appendage; CTI, Cavo-tricuspid isthmus; MAC, Minimal alveolar concentration; FAM, Fast-anatomical map.

Acknowledgement: This trial is investigator-led and non-commercial. No sources of funding outside standard health insurance payments were used.

Author contributions: All authors substantially contributed to the conception of the study, to the acquisition, analysis and interpretation of data and have approved the final version of the manuscript.

Conflict of interest statement: The authors state that there is no conflict of interest regarding the publication of this article.

REFERENCES


186